Category Archives: OTC

Pulse Seismic Inc. (PLSDF: OTCQX International) | Pulse Seismic Inc. to hold year end 2014 conference call


CALGARY, Feb. 26, 2015 /CNW/ – Pulse Seismic Inc. (“Pulse” or the “Company”) will hold a conference call and live audio webcast on Friday, March 6, 2015 at 11:00 a.m.(MST) (1:00 p.m. EST)  to discuss the Company’s  2014 results.

A news release announcing Pulse’s results will be issued on Thursday, March 5, 2015. The related financial statements and M D and A will be filed concurrently on SEDAR. A news release containing preliminary unaudited selected financial information was previously issued on January 19, 2015.

The call will be hosted by Neal Coleman, President and CEO, and Pamela Wicks, VP Finance and CFO. Following management’s presentation there will be a question-and-answer session.

To participate please dial 587-880-2171 (local – Calgary) or 1-888-390-0546 (toll free – North America) approximately 10 minutes before the commencement of the call. To listen to the webcast of the conference call please visit the Company’s website at

An archival recording of the conference call will be available approximately one hour after the completion of the call until March 13, 2015. To access the replay, please dial 1-888-390-0541 or 416-764-8677 and enter the playback pass code 997259#.


Pulse is a market leader in the acquisition, marketing and licensing of 2D and 3D seismic data to the western Canadian energy sector. Pulse owns the second-largest licensable seismic data library in Canada, currently consisting of approximately 28,300 square kilometres of 3D seismic and 340,000 kilometres of 2D seismic. The library extensively covers the Western Canada Sedimentary Basin where most of Canada’s oil and natural gas exploration and development occur.  

SOURCE Pulse Seismic Inc.

Article source:

SQI Diagnostics Inc. (SQIDF: OTCQX International) | SQI Diagnostics Reports First Quarter Financial Results

Continues to Build on Fiscal 2014 Achievements

TORONTO, Feb. 26, 2015 /PRNewswire/ – SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today reported its financial and operational results for the fiscal first quarter ended December  31, 2014. All figures in this press release are in Canadian dollars (CAD), unless otherwise stated.

“During the quarter the Company continued to win new business from our existing customers and add to our sales pipeline,” said Andrew Morris, President and CEO of SQI.  “We expect this additional business to result in the installation of multiple platforms which are the basis for sustainable and on-going revenue growth through the sale of custom and other high volume test products.”

Highlights for the Quarter

  • Our first global pharmaceutical customer has agreed to a consignment sqidlite instrument planned for March 2015 delivery. This global pharma client will evaluate the performance of the sqidlite instrument and two immunogenicity tests developed by SQI, one of which was completed during our first quarter of fiscal 2015. We believe successful evaluation of the instrument and test kits will lead to the purchase of the sqidlite instrument and on-going purchases of test kits.
  • We announced a follow-on agreement and technology transfer agreement that expands our partnership with our diagnostic customer in the infectious disease-DNA market.
  • We secured a second project from a global pharmaceutical company previously referred to as Global Pharma 3. This second project is meaningful as it is our third global-sized drug development customer that has initiated repeat business.
  • We completed the development work for our fourth global pharmaceutical customer. We are confident that we will sell this customer one or more SQI platform(s), as well as kits for human studies for this project during the second half of fiscal 2015. We are in discussions with this customer to develop tests for additional projects relating to other new drugs in their pipeline. Subsequent to the period end, this customer presented select data from this development project at the Immunogenicity and Immunotoxicity conference.
  • We re-established our IVD, regulated product capability by attaining FDA clearance for our newest multiplexed celiac diagnostic test. This diagnostic test comprises four individual tests that we have multiplexed into a single test and that is used to aid in the diagnosis of celiac disease. Celiac disease is a leading gastrointestinal illness, reported to occur in 1 in 130 North Americans.
  • We continued to expand our pipeline of customers and are in various stages of negotiation with customers for multiple new development projects including: a cardiac biomarker assay; a veterinary assay; and, an immunogenicity assay for use by a US-based CRO. Subsequent to the quarter end, we brought one of these opportunities to fruition and are in active discussions with numerous remaining prospects.
  • On January 30, 2015 and on February 20, 2015 the Company completed two tranches of a debenture financing resulting in gross proceeds of $3,236,000.

Financial Results Overview

During the first quarter of fiscal 2015 the Company continued to record revenue from product and services sales in our DDTS business.  Revenue for the three months ended December 31, 2014 was $15,000 compared to $2,000 for the same period last year.  Revenue in the first quarter of fiscal 2015 includes fess earned for the technology transfer phase of the project to manufacture a DNA-based pathogen detection test as well as for additional work contracted by one of our global pharma customers.

For the quarter-ended December 31, 2014, the Company recorded a net loss of $1,365,000 ($0.02 net loss per share) compared to a net loss of $1,501,000 ($0.03 net loss per share) for the quarter-ended December 31, 2013. The net loss was lower for the three months ended December 31, 2014 as compared to the same period last year due mainly to decreases in RD expenditures as discussed below.

RD expenditures, excluding amortization and stock based compensation, for the three months ended December 31, 2014 were $684,000 compared to $840,000 for the three months ended December 31, 2013. RD costs were lower for the three months ended December 31, 2014 as compared to the same period last year.   In the quarter-ended December 31, 2013 the Company incurred significant costs related to the verification and validation of Celiac DGP. There were no assays in the validation or verification stages in the current quarter.  In addition the Company incurred lower RD salary and related costs in the first quarter of fiscal 2015 as compared to the first quarter of fiscal 2014 due to staff reductions made in February of 2014 and other temporary staff changes during the quarter.  

Corporate and general expenses, excluding stock-based compensation, were $359,000 for the quarter-ended December 31, 2014 compared to $298,000 for the quarter-ended December 31, 2013.   The increase is due to fees incurred in the OTCQX listing process and as a result of investor relations initiatives pursued to increase investor awareness. 

Sales and marketing expenses, excluding stock based compensation, totalled $160,000 for the three months ended December 31, 2014 compared to $150,000 for the three months ended December 31, 2013. The increase in sales and marketing expenses is primarily due to the addition of one individual to the sales and marketing area.  Sales and marketing expenses in the quarter-ended December 31, 2013 include a bonus paid for the execution of 3 commercial contracts, there were no bonuses paid in the quarter-ended December 31, 2014.

At December 31, 2014, current assets were $744,000 compared to $2,058,000 at September 30, 2014. As at December 31, 2014 the Company has a $342,000 working capital surplus compared to a surplus of $1,625,000 at September 30, 2014.  As noted above, the Company completed a financing shortly after the quarter end.

Conference Call Details

President and CEO, Andrew Morris, along with Company management, will host a conference call today to review financial results and discuss business developments for the period.  Details are as below:


An archived copy of the conference call will be available for 90 days on the Company website at  and also at

Detailed financial statements and the management’s discussion and analysis (MDA) will also be made available on the Company website at and at

About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit

Forward-looking Statements
This press release contains certain statements including, without limitation, the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”, “position” “possible”, “is subject to” and other similar expressions which may constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated.  Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI’s ability to raise additional funds in the future.

Such statements, risks and uncertainties are detailed in the Company’s ongoing filings with the securities regulatory authorities, and are available to the public at The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE SQI Diagnostics Inc.

Article source:

N1 Technologies Inc. (NTCHF: OTC Pink Current) | N1 Technologies Inc. Patents NanoBolt Battery

BELIZE CITY, Belize, Feb. 26, 2015 /PRNewswire/ — The directors and management of N1 Technologies Inc. (OTC PINK: NTCHF) has filed for a patent on their revolutionary nano engineered Lithium Tungsten Battery. The patent improves upon the current lithium ion battery technology by adding Tungsten and Carbon nanotubes to the Anode materials. The multi layered nanotubes create a vast area for ions to be stored, increasing recharge rates and overall endurance. The company is planning to work with battery manufacturers to create a high performance replacement battery for existing hybrid and electric vehicles. The new technology can also be added to a wide array of current lithium designs.  

N1 Technologies Inc. is a Global leader in Nanotechnology Research and Development. The company innovates, manufactures and markets a wide range of nano engineered advanced products, under the trade names of, NanoSave,  NanoSave N1, Tungstalon, Tungsten Hull Coat, NanoBolt Batteries, Velocitron Engines and Fridgenator. The company has an exclusive distribution agreement with Amazon and sells direct to the public in dozens of countries. N1 Technologies Inc. has a number of new and revolutionary Nano Engineered products currently in it’s development pipeline.  Additional information regarding the company and it’s diverse product line will be forthcoming in the near future.


Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “will” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.


To view the original version on PR Newswire, visit:

SOURCE N1 Technologies Inc.

Article source:

Bunk Beds